Mortality from venous thromboembolism among young women in Europe: No evidence for any effect of third generation oral contraceptives

Journal of Epidemiology and Community Health

Volumn 51, Issue 6, 1997, Pages 630-635

  Farmer, R D T ^a   Newson, R B ^a   MacRae, K ^a   Lawrenson, R A ^a   Tyrer, F ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; EUROPE; FEMALE; HUMAN; MORTALITY; NORMAL HUMAN; POPULATION RESEARCH; REGRESSION ANALYSIS; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0031468184     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.51.6.630     Document Type: Article

References (20)

1. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
2. Farley TMM, Meirik O, Chang CL, Marmot MG, Poulter NR. World Health Organisation Collarorative Study on Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
3. Spitzer WO, Lewis MA, Heinemann LAJ, Thprogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8.
4. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Buller HR, Vandenbroucke JP. Enhancement of factor V Leiden mutation on the risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995;346:1593-6.
5. Carnall D, Karcher H, Lie LG, Sheldon T, Spurgeon D, Josefson D, et al. Third generation oral contraceptives - the controversy. BMJ 1995;311:1589-90.
6. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer W, with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestogens: the role of bias in observational research. Contraception 1996;54:5-13.
7. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and the risk of myocardial infarction: an international case-control study. BMJ 1996;312:88-90.
8. McPherson K. Third generation oral contraception and venous thromboembolism. BMJ 1996;312:68-9.
9. Vandenbroucke JP, Bloemenkamp KWM, Heimerhorst FM, Rosendaal FR. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996;348:401-2.
10. Thomas SHL. Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales. Lancet 1996;348:402.
11. Farmer R, Lewis M. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996;348:1095.
12. Van Lunsen RHW. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996;348:1095-6.
13. Rai H, ed. Data catalogue. 1st ed. London: IMS Global Services, 1995:18-30.
14. SAS Institute Inc. SAS Technical Report P-243, SAS/STAT Software: The GENMOD Procedure, Release 6.09. Gary, North Carolina: SAS Institute Inc, 1993.
15. Office of Population Censuses and Surveys (OPCS). Mortality statistics: cause 1993, series DH2 no 20. London: HMSO, 1995:x-xi.
16. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995;15:195-200.
17. de Swiet M. Thromboembolism. In: de Swiet M, ed. Medical disorders in obstetric practice.3rd ed. Oxford: Blackwell Science, 1995:117-42.
18. Paul C. Oral contraceptives and venous thromboembolism. N Z Med J 1996;109:413-15.
19. Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of venous thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979;110:188-95.
20. Thomas SHL. Author's reply. Lancet 1996;348:1097.